Follow the people · Insider
Kristopher Hanson
Kristopher Hanson files insider transactions with the SEC as a general counsel of MapLight Therapeutics (MPLT). We hold 7 disclosed purchases and sales filed since 7 October 2019, 3 of them in the last 90 days.
- Files forMPLT
- Disclosed buys and sells7 in all, 3 in the last 90 days
- Last disclosure19 August 2026
Positions held
2 posts we hold — a term names its own dates; a run of filings only says when they filed- Filed 27 October 2025 — 17 August 2026General Counsel · MapLight Therapeutics (MPLT)28 Form 4 lines · source: SEC Form 4
- Filed 7 October 2019 — 20 May 2022SVP and General Counsel · PhaseBio Pharmaceuticals (PHAS)9 Form 4 lines · source: SEC Form 4
Everything they disclosed
37 entries, newest first — one per disclosure report, one per Form 4 line- was granted 7,730 shares of MapLight TherapeuticsSEC Form 419 August 2026Voting Common Stock · traded 17 August 2026 · filed 19 August 2026
- was granted 31,395 shares of MapLight Therapeutics (a derivative holding)SEC Form 419 August 2026Employee Stock Option (right to buy) · traded 17 August 2026 · filed 19 August 2026
- ▼ sold on the open market 2,147 shares of MapLight TherapeuticsSEC Form 417 July 2026Voting Common Stock · traded 15 July 2026 · filed 17 July 2026
- ▼ sold on the open market 5,103 shares of MapLight TherapeuticsSEC Form 417 July 2026Voting Common Stock · traded 15 July 2026 · filed 17 July 2026
- ▼ sold on the open market 10 shares of MapLight TherapeuticsSEC Form 417 July 2026Voting Common Stock · traded 15 July 2026 · filed 17 July 2026
- ▼ sold on the open market 4,776 shares of MapLight TherapeuticsSEC Form 417 July 2026Voting Common Stock · traded 16 July 2026 · filed 17 July 2026
- ▼ sold on the open market 3,331 shares of MapLight TherapeuticsSEC Form 417 July 2026Voting Common Stock · traded 16 July 2026 · filed 17 July 2026
- ▼ sold on the open market 11 shares of MapLight TherapeuticsSEC Form 417 July 2026Voting Common Stock · traded 16 July 2026 · filed 17 July 2026
- ▼ sold on the open market 1,130 shares of MapLight TherapeuticsSEC Form 417 July 2026Voting Common Stock · traded 17 July 2026 · filed 17 July 2026
- ▼ sold on the open market 284 shares of MapLight TherapeuticsSEC Form 411 May 2026Voting Common Stock · traded 11 May 2026 · filed 11 May 2026
- ▼ sold on the open market 846 shares of MapLight TherapeuticsSEC Form 411 May 2026Voting Common Stock · traded 11 May 2026 · filed 11 May 2026
- ▼ sold on the open market 6,979 shares of MapLight TherapeuticsSEC Form 411 May 2026Voting Common Stock · traded 11 May 2026 · filed 11 May 2026
- ▼ sold on the open market 5,808 shares of MapLight TherapeuticsSEC Form 411 May 2026Voting Common Stock · traded 11 May 2026 · filed 11 May 2026
- ▼ sold on the open market 9,030 shares of MapLight TherapeuticsSEC Form 46 May 2026Voting Common Stock · traded 4 May 2026 · filed 6 May 2026
- ▼ sold on the open market 3,908 shares of MapLight TherapeuticsSEC Form 46 May 2026Voting Common Stock · traded 4 May 2026 · filed 6 May 2026
- ▼ sold on the open market 296 shares of MapLight TherapeuticsSEC Form 46 May 2026Voting Common Stock · traded 4 May 2026 · filed 6 May 2026
- ▼ sold on the open market 683 shares of MapLight TherapeuticsSEC Form 46 May 2026Voting Common Stock · traded 4 May 2026 · filed 6 May 2026
- ▼ sold on the open market 1,529 shares of MapLight TherapeuticsSEC Form 417 April 2026Voting Common Stock · traded 15 April 2026 · filed 17 April 2026
- ▼ sold on the open market 73 shares of MapLight TherapeuticsSEC Form 417 April 2026Voting Common Stock · traded 16 April 2026 · filed 17 April 2026
- ▼ sold on the open market 225 shares of MapLight TherapeuticsSEC Form 417 April 2026Voting Common Stock · traded 16 April 2026 · filed 17 April 2026
- was granted 7,730 shares of MapLight TherapeuticsSEC Form 49 February 2026Voting Common Stock · traded 5 February 2026 · filed 9 February 2026
- was granted 31,395 shares of MapLight Therapeutics (a derivative holding)SEC Form 49 February 2026Employee Stock Option (right to buy) · traded 5 February 2026 · filed 9 February 2026
- was granted 31,395 shares of MapLight Therapeutics (a derivative holding)SEC Form 49 February 2026Employee Stock Option (right to buy) · traded 5 February 2026 · filed 9 February 2026
- was granted 7,730 shares of MapLight TherapeuticsSEC Form 49 February 2026Voting Common Stock · traded 5 February 2026 · filed 9 February 2026
- had shares withheld for tax on 26,007 shares of MapLight TherapeuticsSEC Form 429 January 2026Voting Common Stock · traded 27 January 2026 · filed 29 January 2026
- had shares withheld for tax on 26,007 shares of MapLight TherapeuticsSEC Form 429 January 2026Voting Common Stock · traded 27 January 2026 · filed 29 January 2026
- was granted 110,046 shares of MapLight Therapeutics (a derivative holding)SEC Form 428 October 2025Employee Stock Option (right to buy) · traded 27 October 2025 · filed 28 October 2025
- was granted 27,098 shares of MapLight TherapeuticsSEC Form 428 October 2025Voting Common Stock · traded 27 October 2025 · filed 28 October 2025
- was granted 4,831 shares of PhaseBio PharmaceuticalsSEC Form 424 May 2022Common Stock · traded 20 May 2022 · filed 24 May 2022
- was granted 18,750 shares of PhaseBio Pharmaceuticals (a derivative holding)SEC Form 428 February 2022Restricted Stock Unit · traded 24 February 2022 · filed 28 February 2022
- was granted 87,500 shares of PhaseBio Pharmaceuticals (a derivative holding)SEC Form 428 February 2022Employee Stock Option (right to buy) · traded 24 February 2022 · filed 28 February 2022
- was granted 1,545 shares of PhaseBio PharmaceuticalsSEC Form 423 November 2021Common Stock · traded 19 November 2021 · filed 23 November 2021
- was granted 1,088 shares of PhaseBio PharmaceuticalsSEC Form 424 May 2021Common Stock · traded 20 May 2021 · filed 24 May 2021
- was granted 36,000 shares of PhaseBio Pharmaceuticals (a derivative holding)SEC Form 49 February 2021Employee Stock Option (right to buy) · traded 5 February 2021 · filed 9 February 2021
- was granted 999 shares of PhaseBio PharmaceuticalsSEC Form 423 November 2020Common Stock · traded 20 November 2020 · filed 23 November 2020
- was granted 55,000 shares of PhaseBio Pharmaceuticals (a derivative holding)SEC Form 414 February 2020Employee Stock Option (right to buy) · traded 12 February 2020 · filed 14 February 2020
- was granted 66,000 shares of PhaseBio Pharmaceuticals (a derivative holding)SEC Form 47 October 2019Employee Stock Option (right to buy) · traded 7 October 2019 · filed 7 October 2019
Positions come from the unitedstates/congress-legislators roster, the Office of Government Ethics and the SEC’s Form 4 index. Every disclosed line names its own source and links the document the government published; we print what the filing says and never a price we did not read from it. Headlines and links come from the GDELT Global Knowledge Graph — the story stays with the publisher. The portrait, where we have one, is the public-domain Congressional Bioguide photograph.